Literature DB >> 24352471

Divergent antibody subclass and specificity profiles but not protective HLA-B alleles are associated with variable antibody effector function among HIV-1 controllers.

Jennifer I Lai1, Anna F Licht, Anne-Sophie Dugast, Todd Suscovich, Ickwon Choi, Chris Bailey-Kellogg, Galit Alter, Margaret E Ackerman.   

Abstract

UNLABELLED: Understanding the coordination between humoral and cellular immune responses may be the key to developing protective vaccines, and because genetic studies of long-term HIV-1 nonprogressors have associated specific HLA-B alleles with spontaneous control of viral replication, this subject group presents an opportunity to investigate relationships between arms of the adaptive immune system. Given evidence suggesting that cellular immunity may play a role in viral suppression, we sought to determine whether and how the humoral immune response might vary among controllers. Significantly, Fc-mediated antibody effector functions have likewise been associated with durable viral control. In this study, we compared the effector function and biophysical features of HIV-specific antibodies in a cohort of controllers with and without protective HLA-B alleles in order to investigate whether there was evidence for multiple paths to HIV-1 control, or whether cellular and humoral arms of immunity might exhibit coordinated profiles. However, with the exception of IgG2 antibodies to gp41, HLA status was not associated with divergent humoral responses. This finding did not result from uniform antibody responses across subjects, as controllers could be regrouped according to strong differences in their HIV-specific antibody subclass specificity profiles. These divergent antibody profiles were further associated with significant differences in nonneutralizing antibody effector function, with levels of HIV-specific IgG1 acting as the major distinguishing factor. Thus, while HLA background among controllers was associated with minimal differences in humoral function, antibody subclass and specificity profiles were associated with divergent effector function, suggesting that these features could be used to make functional predictions. Because these nonneutralizing antibody activities have been associated with spontaneous viral control, reduced viral load, and nonprogression in infected subjects and protection in vaccinated subjects, understanding the specific features of IgGs with potentiated effector function may be critical to vaccine and therapeutic antibody development. IMPORTANCE: In this study, we investigated whether the humoral and cellular arms of adaptive immunity exhibit coordinated or compensatory activity by studying the antibody response among HIV-1 controllers with different genetic backgrounds.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24352471      PMCID: PMC3958053          DOI: 10.1128/JVI.03130-13

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  37 in total

1.  Determining the phagocytic activity of clinical antibody samples.

Authors:  Elizabeth G McAndrew; Anne-Sophie Dugast; Anna F Licht; Justin R Eusebio; Galit Alter; Margaret E Ackerman
Journal:  J Vis Exp       Date:  2011-11-30       Impact factor: 1.355

Review 2.  Emerging concepts on the role of innate immunity in the prevention and control of HIV infection.

Authors:  Margaret E Ackerman; Anne-Sophie Dugast; Galit Alter
Journal:  Annu Rev Med       Date:  2011-11-08       Impact factor: 13.739

3.  Antibody-dependent cellular cytotoxicity-mediating antibodies from an HIV-1 vaccine efficacy trial target multiple epitopes and preferentially use the VH1 gene family.

Authors:  Mattia Bonsignori; Justin Pollara; M Anthony Moody; Michael D Alpert; Xi Chen; Kwan-Ki Hwang; Peter B Gilbert; Ying Huang; Thaddeus C Gurley; Daniel M Kozink; Dawn J Marshall; John F Whitesides; Chun-Yen Tsao; Jaranit Kaewkungwal; Sorachai Nitayaphan; Punnee Pitisuttithum; Supachai Rerks-Ngarm; Jerome H Kim; Nelson L Michael; Georgia D Tomaras; David C Montefiori; George K Lewis; Anthony DeVico; David T Evans; Guido Ferrari; Hua-Xin Liao; Barton F Haynes
Journal:  J Virol       Date:  2012-08-15       Impact factor: 5.103

4.  Immune-correlates analysis of an HIV-1 vaccine efficacy trial.

Authors:  Barton F Haynes; Peter B Gilbert; M Juliana McElrath; Susan Zolla-Pazner; Georgia D Tomaras; S Munir Alam; David T Evans; David C Montefiori; Chitraporn Karnasuta; Ruengpueng Sutthent; Hua-Xin Liao; Anthony L DeVico; George K Lewis; Constance Williams; Abraham Pinter; Youyi Fong; Holly Janes; Allan DeCamp; Yunda Huang; Mangala Rao; Erik Billings; Nicos Karasavvas; Merlin L Robb; Viseth Ngauy; Mark S de Souza; Robert Paris; Guido Ferrari; Robert T Bailer; Kelly A Soderberg; Charla Andrews; Phillip W Berman; Nicole Frahm; Stephen C De Rosa; Michael D Alpert; Nicole L Yates; Xiaoying Shen; Richard A Koup; Punnee Pitisuttithum; Jaranit Kaewkungwal; Sorachai Nitayaphan; Supachai Rerks-Ngarm; Nelson L Michael; Jerome H Kim
Journal:  N Engl J Med       Date:  2012-04-05       Impact factor: 91.245

Review 5.  Immunogenetics of spontaneous control of HIV.

Authors:  Mary Carrington; Bruce D Walker
Journal:  Annu Rev Med       Date:  2012       Impact factor: 13.739

6.  High-throughput, multiplexed IgG subclassing of antigen-specific antibodies from clinical samples.

Authors:  Eric P Brown; Anna F Licht; Anne-Sophie Dugast; Ickwon Choi; Chris Bailey-Kellogg; Galit Alter; Margaret E Ackerman
Journal:  J Immunol Methods       Date:  2012-09-27       Impact factor: 2.303

7.  Antibody-dependent cell-mediated viral inhibition emerges after simian immunodeficiency virus SIVmac251 infection of rhesus monkeys coincident with gp140-binding antibodies and is effective against neutralization-resistant viruses.

Authors:  Mohammed Asmal; Yue Sun; Sophie Lane; Wendy Yeh; Stephen D Schmidt; John R Mascola; Norman L Letvin
Journal:  J Virol       Date:  2011-03-30       Impact factor: 5.103

8.  Recombinant gp120 vaccine-induced antibodies inhibit clinical strains of HIV-1 in the presence of Fc receptor-bearing effector cells and correlate inversely with HIV infection rate.

Authors:  Donald N Forthal; Peter B Gilbert; Gary Landucci; Tran Phan
Journal:  J Immunol       Date:  2007-05-15       Impact factor: 5.422

9.  Isotype-switched immunoglobulin G antibodies to HIV Gag proteins may provide alternative or additional immune responses to 'protective' human leukocyte antigen-B alleles in HIV controllers.

Authors:  Martyn A French; Rob J Center; Kim M Wilson; Ibrahim Fleyfel; Sonia Fernandez; Anna Schorcht; Ivan Stratov; Marit Kramski; Stephen J Kent; Anthony D Kelleher
Journal:  AIDS       Date:  2013-02-20       Impact factor: 4.177

10.  ADCC develops over time during persistent infection with live-attenuated SIV and is associated with complete protection against SIV(mac)251 challenge.

Authors:  Michael D Alpert; Jackson D Harvey; W Anderson Lauer; R Keith Reeves; Michael Piatak; Angela Carville; Keith G Mansfield; Jeffrey D Lifson; Wenjun Li; Ronald C Desrosiers; R Paul Johnson; David T Evans
Journal:  PLoS Pathog       Date:  2012-08-23       Impact factor: 6.823

View more
  32 in total

Review 1.  The dysfunction of T follicular helper cells.

Authors:  Rafael Cubas; Matthieu Perreau
Journal:  Curr Opin HIV AIDS       Date:  2014-09       Impact factor: 4.283

2.  Genetic variants of Fcγ (GM allotypes) and the Fc-mediated effector functions in HIV-1 controllers.

Authors:  Janardan P Pandey
Journal:  J Virol       Date:  2014-06       Impact factor: 5.103

Review 3.  Immune responses during spontaneous control of HIV and AIDS: what is the hope for a cure?

Authors:  A Saez-Cirion; B Jacquelin; F Barré-Sinoussi; M Müller-Trutwin
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2014-05-12       Impact factor: 6.237

4.  HIV-1 Control and Immunoglobulin Genes.

Authors:  Janardan P Pandey
Journal:  J Infect Dis       Date:  2018-03-13       Impact factor: 5.226

Review 5.  Systems serology for evaluation of HIV vaccine trials.

Authors:  Margaret E Ackerman; Dan H Barouch; Galit Alter
Journal:  Immunol Rev       Date:  2017-01       Impact factor: 12.988

Review 6.  Systems serology for decoding infection and vaccine-induced antibody responses to HIV-1.

Authors:  Srivamshi Pittala; Kyle S Morrison; Margaret E Ackerman
Journal:  Curr Opin HIV AIDS       Date:  2019-07       Impact factor: 4.283

7.  Temporal variation in HIV-specific IgG subclass antibodies during acute infection differentiates spontaneous controllers from chronic progressors.

Authors:  Saheli Sadanand; Jishnu Das; Amy W Chung; Matthew K Schoen; Sophie Lane; Todd J Suscovich; Hendrik Streeck; Davey M Smith; Susan J Little; Douglas A Lauffenburger; Douglas D Richman; Galit Alter
Journal:  AIDS       Date:  2018-02-20       Impact factor: 4.177

8.  Viremic HIV Controllers Exhibit High Plasmacytoid Dendritic Cell-Reactive Opsonophagocytic IgG Antibody Responses against HIV-1 p24 Associated with Greater Antibody Isotype Diversification.

Authors:  M Christian Tjiam; James P A Taylor; Mazmah A Morshidi; Lucy Sariputra; Sally Burrows; Jeffrey N Martin; Steven G Deeks; Dino B A Tan; Silvia Lee; Sonia Fernandez; Martyn A French
Journal:  J Immunol       Date:  2015-04-24       Impact factor: 5.422

9.  Broadly neutralizing anti-HIV-1 antibodies require Fc effector functions for in vivo activity.

Authors:  Stylianos Bournazos; Florian Klein; John Pietzsch; Michael S Seaman; Michel C Nussenzweig; Jeffrey V Ravetch
Journal:  Cell       Date:  2014-09-11       Impact factor: 41.582

10.  Designer α1,6-Fucosidase Mutants Enable Direct Core Fucosylation of Intact N-Glycopeptides and N-Glycoproteins.

Authors:  Chao Li; Shilei Zhu; Christopher Ma; Lai-Xi Wang
Journal:  J Am Chem Soc       Date:  2017-10-16       Impact factor: 15.419

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.